Repositorio Dspace

First month prednisone dose predicts prednisone burden during the following 11 months: an observational study from the RELES cohort.

Mostrar el registro sencillo del ítem

dc.contributor.author Ruiz-Irastorza, G
dc.contributor.author García, M
dc.contributor.author Espinosa, G
dc.contributor.author Caminal, L
dc.contributor.author Mitjavila, F
dc.contributor.author González-Leon, R
dc.contributor.author Sopena, B
dc.contributor.author Canora, J
dc.contributor.author Villalba, M-V
dc.contributor.author Rodríguez-Carballeira, M
dc.contributor.author López-Dupla, J-M
dc.contributor.author Callejas, J-L
dc.contributor.author Castro, A
dc.contributor.author Tolosa, C
dc.contributor.author Sánchez-García, M-E
dc.contributor.author Pérez-Conesa, M
dc.contributor.author Navarrete-Navarrete, N
dc.contributor.author Rodríguez, A-P
dc.contributor.author Herranz-Marín, María-Teresa
dc.contributor.author Pallares, L
dc.date.accessioned 2026-10-21T06:05:22Z
dc.date.available 2026-10-21T06:05:22Z
dc.date.issued 2016-08
dc.identifier.citation Ruiz-Irastorza G, Garcia M, Espinosa G, Caminal L, Mitjavila F, González-León R, et al. First month prednisone dose predicts prednisone burden during the following 11 months: an observational study from the RELES cohort. Lupus Sci Med. agosto de 2016;3(1):e000153. doi:10.1136/lupus-2016-000153
dc.identifier.issn 2053-8790
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/28695
dc.description.abstract AIM: To study the influence of prednisone dose during the first month after systemic lupus erythematosus (SLE) diagnosis (prednisone-1) on glucocorticoid burden during the subsequent 11 months (prednisone-2-12). METHODS: 223 patients from the Registro Español de Lupus Eritematoso Sistémico inception cohort were studied. The cumulative dose of prednisone-1 and prednisone-2-12 were calculated and recoded into a four-level categorical variable: no prednisone, low dose (up to 7.5 mg/day), medium dose (up to 30 mg/day) and high dose (over 30 mg/day). The association between the cumulative prednisone-1 and prednisone-2-12 doses was tested. We analysed whether the four-level prednisone-1 categorical variable was an independent predictor of an average dose >7.5 mg/day of prednisone-2-12. Adjusting variables included age, immunosuppressives, antimalarials, methyl-prednisolone pulses, lupus nephritis and baseline SLE Disease Activity Index (SLEDAI). RESULTS: Within the first month, 113 patients (51%) did not receive any prednisone, 24 patients (11%) received average low doses, 46 patients (21%) received medium doses and 40 patients (18%) received high doses. There was a strong association between prednisone-1 and prednisone-2-12 dose categories (p<0.001). The cumulative prednisone-1 dose was directly associated with the cumulative prednisone-2-12 dose (p<0.001). Compared with patients on no prednisone, patients taking medium (adjusted OR 5.27, 95% CI 2.18 to 12.73) or high-dose prednisone-1 (adjusted OR 10.5, 95% CI 3.8 to 29.17) were more likely to receive prednisone-2-12 doses of >7.5 mg/day, while patients receiving low-dose prednisone-1 were not (adjusted OR 1.4, 95% CI 0. 0.38 to 5.2). If the analysis was restricted to the 158 patients with a baseline SLEDAI of ?6, the model did not change. CONCLUSION: The dose of prednisone during the first month after the diagnosis of SLE is an independent predictor of prednisone burden during the following 11 months.
dc.language.iso eng
dc.rights Atribución/Reconocimiento-NoComercial 4.0 Internacional
dc.rights.uri https://creativecommons.org/licenses/by-nc/4.0/deed.es  *
dc.title First month prednisone dose predicts prednisone burden during the following 11 months: an observational study from the RELES cohort.
dc.type info:eu-repo/semantics/article 
dc.identifier.pmid 27547439
dc.relation.publisherversion https://lupus.bmj.com/lookup/doi/10.1136/lupus-2016-000153
dc.identifier.doi 10.1136/lupus-2016-000153
dc.journal.title Lupus Science & Medicine


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento-NoComercial 4.0 Internacional Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento-NoComercial 4.0 Internacional

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta